Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
VistaGen Therapeutics (NASDAQ: VTGN) reported its fiscal 2021 Q2 financial results for the quarter ending September 30, 2020. The company demonstrated a reduced net loss of approximately $3.7 million, down from $5.7 million in the prior year. Revenue for the quarter was $334,000 associated with a $5 million upfront license payment from EverInsight Therapeutics. R&D expenses decreased significantly to $2.4 million, reflecting the completion of previous clinical studies. VistaGen is advancing its CNS pipeline, preparing for a pivotal Phase 3 study of PH94B for social anxiety disorder set to launch in Q2 2021.
VistaGen Therapeutics (NASDAQ: VTGN) announced new in vitro data showing that PH94B, an intranasal treatment for social anxiety disorder, does not activate GABA-A receptors, differentiating it from benzodiazepines. This suggests that PH94B may avoid common side effects, such as sedation and addiction, making it a safer alternative for treating anxiety. With the FDA's Fast Track designation for PH94B, the company aims to address rising anxiety disorders exacerbated by current societal stressors, moving towards pivotal Phase 3 development.
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in the Guggenheim Healthcare Talks, specifically at the 2nd Annual Neuro/Immunology Day on November 16, 2020. This virtual event will focus on neurological and immunological diseases, highlighting both established and emerging companies. VistaGen is dedicated to developing innovative treatments for anxiety, depression, and other CNS disorders, and is committed to exceeding current treatment standards. For more details, visit www.vistagen.com.
VistaGen Therapeutics (NASDAQ: VTGN) has received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement, now having until April 12, 2021. This extension does not impact the company's current listing status on the Nasdaq Capital Market. CEO Shawn K. Singh expressed optimism about regaining compliance while advancing their three CNS drug candidates aimed at addressing anxiety and depression disorders.
VistaGen Therapeutics (VTGN) announced promising data from its second preclinical study of AV-101 combined with probenecid, which may enhance the treatment of central nervous system (CNS) disorders. The study showed that the combination significantly raised brain levels of AV-101's active metabolite, 7-Cl-KYN, improving its therapeutic potential. AV-101, with an excellent safety profile and no significant side effects, could offer a new treatment option for anxiety and depression. The findings could lead to further clinical development under FDA's Fast Track designation for both major depressive disorder and neuropathic pain.
VistaGen Therapeutics (Nasdaq: VTGN), a biopharmaceutical firm focused on CNS disorders, will present at the LD Micro 500 Virtual Conference from September 1-4, 2020. CEO Shawn Singh will speak on September 3 at 11 a.m. EDT. Investors can watch the live webcast by registering online. VistaGen's pipeline includes three drug candidates targeting anxiety and depression, all showing promising safety profiles. The presentation aims to highlight the company's innovative approach to treating CNS disorders and its position within the micro-cap market.
VistaGen Therapeutics (Nasdaq: VTGN) reported its fiscal 2021 Q1 results, highlighting key advancements in its drug development pipeline. The Company reached an agreement with the FDA on PH94B's Phase 3 study for social anxiety disorder, with enrollment for 182 adults planned. Financially, VistaGen secured a $5 million non-dilutive license payment and completed a public offering, raising approximately $14.29 million. Notably, net loss decreased to $3.5 million, while R&D expenses dropped from $4.3 million to $1.7 million compared to the previous year.
VistaGen Therapeutics (Nasdaq: VTGN) announced that underwriters of its public offering exercised their over-allotment option, bringing additional gross proceeds of approximately $1.79 million. Overall, the offering totaled $14.29 million with 17,868,250 shares issued. The funds will support the development of CNS pipeline programs, general research, and working capital. Maxim Group LLC managed the offering, which was conducted under an effective shelf registration statement with the SEC.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) has closed an underwritten public offering of 15,625,000 shares at $0.80 per share, generating $12.5 million in gross proceeds. The proceeds will support the development of CNS pipeline programs, R&D, and general corporate purposes. An option for underwriters to purchase up to an additional 2,343,750 shares within 45 days is also granted. The offering was conducted under an effective shelf registration statement.
VistaGen Therapeutics (NASDAQ: VTGN) received a $5 million non-dilutive upfront license payment from EverInsight Therapeutics for the development of PH94B, a nasal spray targeting anxiety-related disorders. This collaboration focuses on commercializing PH94B in key Asian markets, including Greater China and Southeast Asia.
VistaGen is eligible for milestone payments and royalties on future sales. The FDA has granted Fast Track designation for PH94B's Phase 3 development as a treatment for social anxiety disorder (SAD), marking it as a potential breakthrough in non-addictive anxiety treatment.
